Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota in Cirrhotic Patients
2 other identifiers
observational
50
1 country
1
Brief Summary
The purpose of this study is to determine the effect of transjugular intrahepatic portosystemic shunt on gut microbiota and associated inflammatory factors in cirrhotic patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 6, 2015
CompletedFirst Posted
Study publicly available on registry
April 28, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2016
CompletedOctober 27, 2015
October 1, 2015
1.7 years
April 6, 2015
October 26, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in fecal microbiota
baseline and 6 month
Secondary Outcomes (2)
Incidence of hepatic encephalopathy
6 month
Changes of blood inflammatory parameter including IL-2(interleukin 2),IL-6,IL-10,IL-8,TNF-α
baseline and 6 month
Study Arms (2)
TIPS group
patients who have transjugular intrahepatic portosystemic shunt
Non-TIPS group
patients who have endoscopic variceal ligation
Eligibility Criteria
Cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt for any indication at West China Hospital
You may qualify if:
- Cirrhotic patients who received TIPS;
- Treatment-naive to TIPS and major operation involving liver such as surgical shunt, hepatic resection and liver transplantation)
You may not qualify if:
- Uncontrolled infection or sepsis;
- Hepatobiliary or pancreatic malignancy or biliary obstruction;
- Vital organ dysfunction;
- Administration of antibiotics (after TIPS and 2 weeks before TIPS);
- Cachexia;
- Pregnant or breeding women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
West China Hospital
Chengdu, Sichuan, 610041, China
Biospecimen
whole blood, serum,stool
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Zhu Wang, PhD
West China Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical Doctor
Study Record Dates
First Submitted
April 6, 2015
First Posted
April 28, 2015
Study Start
August 1, 2014
Primary Completion
April 1, 2016
Study Completion
April 1, 2016
Last Updated
October 27, 2015
Record last verified: 2015-10